Atea Pharmaceuticals, Inc. (AVIR) FinancialsAVIRAtea Pharmaceuticals, Inc.

Evaluating the bottom line, Atea Pharmaceuticals, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -58.14%, provide a clear picture of how effectively AVIR converts its operational activities into shareholder value.

In the context of the broader market, AVIR competes directly with industry leaders such as RZLT and RLMD. With a market capitalization of $399.42M, it holds a significant position in the sector. When comparing efficiency, AVIR's gross margin of N/A stands against RZLT's N/A and RLMD's N/A. Such benchmarking helps identify whether Atea Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

Atea Pharmaceuticals has shown a troubling financial performance, with continuous net losses reported, including -45,440,000 USD in Q1 2026. The company's EPS has been negative, indicating a lack of profitability, and the forward P/E ratio is 0, suggesting no earnings are anticipated in the near future.